Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors

Benzer Materyaller

• Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
  Yazar:: McKee, Alexis, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Review of cardiovascular outcomes trials of sodium – glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists
  Yazar:: North, Emily J., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• CORRIGENDUM FOR “Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM”
  Baskı/Yayın Bilgisi: (2020)
• Erratum to: Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
  Baskı/Yayın Bilgisi: (2021)
• Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults
  Yazar:: Patorno, Elisabetta, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)